Glutamine and tetrapeptide repeat variations affect the biological activity of different mouse interleukin-2 alleles

被引:16
作者
Matesanz, F [1 ]
Alcina, A [1 ]
机构
[1] CSIC, DEPT BIOL CELULAR & INMUNOL, INST PARASITOL & BIOMED, E-18001 GRANADA, SPAIN
关键词
interleukin-2; polymorphism; mutants; purification; polyglutamine; glycosylation site;
D O I
10.1002/eji.1830260802
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mouse interleukin-2 (IL-2) was thought to be encoded by a single allele. We have recently described N-terminal differences in five IL-2 molecules from nine mouse strains analyzed (Matesanz, E, Alcina, A. and Pellicer, A., Immunogenetics 1993. 38: 300). In this study, we isolated and sequenced the cDNA of three polymorphic IL-2 molecules and constructed two recombinant IL-2 molecules to cover representative structural changes and to address the functional significance of these changes using human and mouse cellular assays in vitro. Apart from punctual codon changes, major differences include an expanding CAG codon (translated into glutamine) and the presence of the tetrapeptide Pro-Thr-Ser-Ser repeated 1, 2, or 3.5 times which is also present once in human IL-2. This tetrapeptide repeat includes an O-glycosylation site. These recombinant IL-2 proteins were expressed at high levels in bacteria and purified by preparative SDS-PAGE with a complete activity recovery. Differences in growth-inducing activity on mouse primary splenocytes were observed in some of them, although no differences were observed in proliferative stimulation of CTLL cells. In human peripheral blood lymphocytes and the T cell line Kit-225, the growth stimulation capacity was inversely dependent on the size of the glutamine stretch and the number of tetrapeptide repeats. These results suggest an evolutionary adaptation of the mouse IL-2/IL-2 receptor system that maintains polyglutamine extensions in the IL-2 molecule. In summary, mouse IL-2 polymorphism results in different bioactivities which may determine susceptibility or resistance to disease.
引用
收藏
页码:1675 / 1682
页数:8
相关论文
共 43 条
[1]   SUPPRESSOR FACTOR T-CELL ACTIVATION AND DECREASED INTERLEUKIN-2 ACTIVITY IN EXPERIMENTAL AFRICAN TRYPANOSOMIASIS [J].
ALCINA, A ;
FRESNO, M .
INFECTION AND IMMUNITY, 1985, 50 (02) :382-387
[2]   THE HEAT-SHOCK RESPONSE IN TRYPANOSOMA-CRUZI [J].
ALCINA, A ;
URZAINQUI, A ;
CARRASCO, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 172 (01) :121-127
[3]  
CAPLAN B, 1981, J IMMUNOL, V126, P1351
[4]   TRIPLET REPEAT MUTATIONS IN HUMAN-DISEASE [J].
CASKEY, CT ;
PIZZUTI, A ;
FU, YH ;
FENWICK, RG ;
NELSON, DL .
SCIENCE, 1992, 256 (5058) :784-789
[5]   CLONING, SEQUENCE, AND EXPRESSION OF BOVINE INTERLEUKIN-2 [J].
CERRETTI, DP ;
MCKEREGHAN, K ;
LARSEN, A ;
CANTRELL, MA ;
ANDERSON, D ;
GILLIS, S ;
COSMAN, D ;
BAKER, PE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (10) :3223-3227
[6]   Lack of intermediate-affinity interleukin-2 receptor in mice leads to dependence on interleukin-2 receptor alpha, beta and gamma chain expression for T cell growth [J].
Chastagner, P ;
Moreau, JL ;
Jacques, Y ;
Miyasaka, M ;
Kondo, M ;
Sugamura, K ;
Theze, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (01) :201-206
[7]   IDENTIFICATION OF SPECIFIC RESIDUES OF HUMAN INTERLEUKIN-2 THAT AFFECT BINDING TO THE 70-KDA SUBUNIT (P70) OF THE INTERLEUKIN-2 RECEPTOR [J].
COLLINS, L ;
TSIEN, WH ;
SEALS, C ;
HAKIMI, J ;
WEBER, D ;
BAILON, P ;
HOSKINGS, J ;
GREENE, WC ;
TOOME, V ;
JU, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (20) :7709-7713
[8]  
CONRADT HS, 1989, J BIOL CHEM, V264, P17368
[9]   MUTATION OF ASP(20) OF HUMAN INTERLEUKIN-2 REVEALS A DUAL ROLE OF THE P55 ALPHA-CHAIN OF THE INTERLEUKIN-2 RECEPTOR [J].
FLEMMING, CL ;
RUSSELL, SJ ;
COLLINS, MKL .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (04) :917-921
[10]   HIGH-AFFINITY RECEPTOR-MEDIATED INTERNALIZATION AND DEGRADATION OF INTERLEUKIN-2 IN HUMAN T-CELLS [J].
FUJII, M ;
SUGAMURA, K ;
SANO, K ;
NAKAI, M ;
SUGITA, K ;
HINUMA, Y .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (03) :550-562